UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (sglt-2) inhibition in adults with kidney disease 2023 update

Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-transporter-...

Full description

Bibliographic Details
Main Authors:	Roddick, AJ, Wonnacott, A, Webb, D, Watt, A, Watson, MA, Staplin, N, Riding, A, Lioudaki, E, Kuverji, A, El Kossi, M, Holmes, P, Holloway, M, Fraser, D, Carvalho, C, Burton, JO, Bhandari, S, Herrington, WG, Frankel, AH
Format:	Journal article
Language:	English
Published:	BioMed Central 2023

UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (sglt-2) inhibition in adults with kidney disease 2023 update

Similar Items